Sonova stock holds firm after latest earnings context

Sonova Holding AG (ISIN CH0012549785) is supported by its latest reported fiscal 2024/25 figures, with sales of CHF 3.92 billion and EBIT of CHF 611.9 million. The group reported these numbers for the year ended 31 March 2025, giving investors a fresh reference point even as the share price itself is not quoted here.

Fiscal 2024/25 in numbers

For fiscal 2024/25, Sonova posted sales of CHF 3.92 billion and EBIT of CHF 611.9 million. The company also reported net income of CHF 490.4 million and free cash flow of CHF 490.1 million for the same period, which shows that profit and cash generation remained closely aligned.

The comparison matters: sales rose from CHF 3.68 billion in fiscal 2023/24 to CHF 3.92 billion in fiscal 2024/25, while EBIT increased from CHF 596.0 million to CHF 611.9 million. Net income also improved from CHF 472.0 million to CHF 490.4 million over the same period.

Profit and cash flow

Sonova said its EBIT margin reached 15.6% in fiscal 2024/25, up from 16.2% a year earlier, while free cash flow stood at CHF 490.1 million after CHF 506.8 million in the prior year. That mix suggests a business that still converts earnings into cash at a high rate, even with a slightly softer margin profile.

Another useful reference is earnings per share of CHF 7.38 in fiscal 2024/25, compared with CHF 7.12 in fiscal 2023/24. The dividend for the year was CHF 4.40 per share, unchanged from the prior year, which keeps the payout framework easy to track.

Hearing care scale

Sonova remains a hearing-care group with two core pillars: hearing aids and cochlear implants. In fiscal 2024/25, the company reported that hearing instruments remained the larger business, while the implants unit continued to be a smaller but strategic part of the group mix.

The product mix matters because Sonova's earnings profile depends on recurring replacement demand, clinic relationships, and technology refresh cycles rather than one-off consumer electronics demand. That makes the fiscal 2024/25 revenue base more informative than any short-term headline.

Product focus

A representative product line is Phonak, Sonova's best-known hearing-aid brand. The brand is part of the companys core hearing-instrument franchise and sits at the center of the group’s sales model in professional audiology channels.

For investors, the product detail matters mainly because Sonova's latest fiscal numbers show how much of the group still depends on premium hearing solutions and the installed-base replacement cycle. The same operating framework that lifted sales to CHF 3.92 billion in fiscal 2024/25 also supports the longer-term earnings base.

Closing price context

Market value is easier to frame than a live quote here: Sonova's latest reported fiscal 2024/25 numbers leave the stock tied to a CHF 3.92 billion revenue base, CHF 611.9 million EBIT, and CHF 490.4 million net income. Those figures provide the most concrete anchor for the share story in this article.